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Abstract More and more companies are advertising and
selling genetic tests directly to consumers. Considering the
ethical, legal, and psychological concerns surrounding
genetic testing in minors, a study of companies’ websites
was performed in order to describe and analyze their pol-
icies with respect to this issue. Of the 29 companies ana-
lyzed, 13 did not provide any information about this matter,
eight companies allowed genetic testing upon parental
request, four companies stated that their website is not
directed to children under 18 years, and four companies
suggested that in order to be tested, applicants should have
reached the age of legal majority. If private companies
offer genetic tests which are also offered in a clinical set-
ting, can they be expected to adhere to the existing clinical
guidelines with regard to these tests? If so, a certain
ambiguity exists. Many companies are emphasizing in their
disclaimers that their services are not medical services and
should not be used as a basis for making medical decisions.
Nonetheless, it remains debatable whether genetic testing
in minors would be appropriate in this context. In line with
the Advisory Committee on Genetic Testing, the Human
Genetics Commission addressed the problem of non-con-
sensual testing and recommended not to supply genetic
testing services directly to those under the age of 16 or to
those not able to make a competent decision regarding
testing.
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Introduction
Advances in genetic knowledge and technologies have
increased the possibilities of testing asymptomatic minors
for late-onset diseases, carrier status or susceptibility to
common complex disorders. These developments have
raised concerns about the ethical, legal and psychological
implications of performing genetic tests in healthy children
and adolescents. Many professional associations have
issued guidelines and position papers to address the issue
of genetic testing in asymptomatic minors in a clinical
context [1]. In general, these guidelines recommend that
the availability of medical intervention is necessary before
predictive genetic testing should be performed in asymp-
tomatic minors. In order to protect the privacy and confi-
dentiality of genetic information and the minor’s right not
to know [2], it has been advanced that testing asymptom-
atic children should be postponed until a minor can par-
ticipate in the decision-making process [3]. It has also been
argued that testing minors potentially creates serious social,
emotional, psychosocial and educational consequences for
the child and his family [4].
More and more companies are advertising and selling
genetic tests directly to consumers (DTC) [5]. Such DTC
genetic testing can be understood as including two related
aspects: firstly, the advertising of genetic tests directly to
consumers; and secondly, the direct access or ordering of
genetic tests without the intermediate of a health care
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professional from the traditional health care system. The types
of genetic tests being offered are extremely varied and include
those that offer information regarding paternity, ancestry,
health enhancement (nutrigenetics, dermatogenetics), drug
response (pharmacogenetics), susceptibility testing for com-
mon complex genetic disorders (cardiovascular diseases,
hereditary hemocromatosis, osteoporosis, type 2 diabetes…),
as well as fetal gender tests (from 5 weeks on). Furthermore,
some companies are offering ‘‘genetic profiles’’ which involve
testing hundreds of thousands of single nucleotide polymor-
phisms (SNPs), the results of which are claimed to provide
personal information regarding susceptibility to many dif-
ferent disorders. Finally, it should be noted, that some com-
panies also offer genetic tests that are commonly offered in
clinical genetics centres, such as those for monogenic disor-
ders like cystic fibrosis and Tay-Sachs.
While proponents of DTC genetic testing argue that the
benefits of offering such services will include increased
access, and greater consumer autonomy, [6, 7] critics point to
several potential risks associated with this type of service.
Among others, concerns have been raised with regard to the
clinical validity and utility of the genetic tests being offered
[8]. Apprehensions have also been presented regarding the
availability and quality of genetic counseling, the qualifica-
tions and impartiality of counselors, the effectiveness of tele-
counseling and the validity of the informed consent process
[9]. Additional concerns revolve around the idea that the
provision of genetic tests outside the health care system may
consequently lead consumers to visit health care professionals
(as a follow up to the genetic test results) and result in an
overconsumption of health care services. Finally, the lack of
regulatory control over DTC genetic testing services has also
been raised as being an important problem [10, 11].
Above and beyond the worries already mentioned, an
additional unease remains: what about the children? What
protection is available when dealing with minors in the
context of DTC genetic testing services? It has been
reported that some companies offering direct-to-consumer
genome scanning services accept requests to process
samples from minors [12]. Since this earlier contribution
only analyzed five companies offering specific services
(testing of a large number of SNPs, or genome scans), we
provide herein, a more complete overview of the current
policies regarding genetic testing in minors based on the
information found on companies’ websites.
Methods
The companies included in this analysis were obtained
from a list published by the Genetics and Public Policy
Center (Johns Hopkins University, November 2008) [13].
Thirty-five companies were included in this list, and were
considered companies which offer ‘‘tests and test inter-
pretation directly to consumers rather than through the
traditional model of health care provider-offered genetic
tests.’’ [13]. Only companies offering health-related
genetic tests that are not explicitly prenatal in nature were
included in the analysis. Companies exclusively offering
paternity, genealogy, or ancestry tests, as well as those
offering DNA matching services (for the main purpose of
finding a romantic partner) were excluded. The entire
content of the companies’ websites, including their consent
forms, terms of services and privacy policy statements
were analyzed in December 2008. All statements or poli-
cies found on the websites and addressing the issue of
genetic testing in minors were listed, analyzed and cate-
gorized. Every website was reviewed independently by PB
and HCH.
Results
Websites from 29 companies (Table 1) were analyzed. Of
the original set of 35 companies considered, one company
had ceased its activities (Smart Genetics), one company
offers only fetal gender testing (ACU-gen Biolabs), one
company offers only prenatal diagnostic services (Niagen)
and two companies offer only DNA matching services
(GenePartner, Scientific Match). Health Tests Direct was
also excluded from the analysis because the company sends
consumers to a ‘blood draw center’ located as close as pos-
sible to the consumer’s home, and the different types of tests
offered change depending on each ‘‘blood draw center’’.
The information presented on companies’ websites
regarding the possibility of performing genetic tests in
minors, was grouped into one of four categories: (1)
companies which do not provide any information on this
issue (Table 1 group A); (2) companies which state that
they will allow genetic testing upon parental request and/or
authorization (Table 1 group B, and Table 2); (3) compa-
nies which make clear that their website is not directed
towards minors but are not explicit about whether they
would refuse testing in minors upon parental request
(Table 1 group C, and Table 3); and (4) companies which
provide information that suggests that their tests are not
directed toward minors (Table 1 group D, and Table 4).
Companies allowing genetic testing in minors upon
parental request and/or authorization
There are eight companies (28%; 8/29) that allow genetic
testing in minors upon parental request (Table 1 group B and
Table 2). Although some companies (e.g. 23andme, DNA
direct) do acknowledge that their services are not ‘‘designed
or intended to attract children under the age of 13’’, in the
P. Borry et al.
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Table 1 List of companies and their genetic tests offered
Company DNA tests offered
Group A: companies that do not provide information on genetic testing in minors
1. DNA dimensions (USA,
www.detroitdna.com)
Alzheimer
2. DNA traits (USA, www.dnatraits.com) Ashkenazi Jews Genetic Disease Panel (25 disorders); Clotting Disorders Panel; Sickle Cell
and b-Thalassemia Panel; All tests from the panels can be purchased individually
3. GeneLink Biosciences (USA,
www.genelinkbio.com)
DNA Based Assessments (Oxidative Stress Assessment, Comprehensive Cardiovascular
Assessment, Bone Health Assessment (Osteo-Health), Healthy Aging Assessment,
DermageneticsTM Skin Health Assessment, CoQ10 Efficiency Assessment, Lipid
Metabolism and Metabolic Syndrome Assessment, Dermagenetics Skin Health);
Dermagenetics Skin Care SystemTM, Nutragenetics Nutritional Care SystemTM
4. G-Nostics (UK, www.g-nostics.com) NicoTestTM
5. Graceful Earth (USA,
www.gracefulearth.com)
Alzheimer
6. Health Check USA (USA,
www.healthcheckusa.com)
Celiac disease DNA test; Combined Factor V Leiden with Prothrombin (Factor II) DNA
Test; Factor V Leiden DNA Test; Factor V Leiden DNA Test; Hereditary
Hemochromatosis; Prothrombin (factor II) DNA Test
7. Holistic Health consultants (USA,
www.holisticheal.com)
Comprehensive Methylation Panel with Methylation Pathway Analysis
8. Knome (USA, www.knome.com) Whole-genome sequencing and comprehensive analysis services for individuals
9. My Genome (USA, www.mygenome.com) Alzheimer’s disease, Cardiovascular disease, Thrombosis, Pregnancy risk, Osteoporosis,
Drug sensitivities
10. New Hope Medical (USA,
www.newhopemedical.org)
12, 19 and 25 SNP panel
11. Proactive Genomics (USA,
www.proactivegenomics.com/)
Focus5TM Prostate Cancer Risk Test
12. Interleukin Genetics (USA,
www.ilgenetics.com)
Periodontal disease (gum disease), GensonaTM Heart Health, GensonaTM General Nutrition
Test
13. Sciona (USA, www.sciona.com;
www.mycellf.com)
Mycellf DNA Fitness Program, Mycellf DNA Nutrition Program
Group B: companies allowing genetic testing in minors upon parental request and/or authorization
1. 23andme (USA, www.23andme.com) Personal genotypes services
2. Consumer genetics (USA,
www.consumergenetics.com)
Asthma Drug Response Test: ß16AsthmaGENTM, Alcohol Metabolism DNA Testing:
WineGENTM, Caffeine Metabolism DNA Testing: CaffeineGENTM
3. Decode (Iceland, www.decodeme.com) decodeme.com Genetic Scan
4. DNA direct (USA, www.dnadirect.com) Alpha-1 Antitrypsin Deficiency, Ashkenazi Jewish Carrier Panel, Blood clotting disorders
(Factor V Leiden), Breast and Ovarian Cancer, Colon cancer screening, Cystic Fibrosis,
Haemochromatosis, Hereditary colon cancer, Infertility, Recurrent pregnancy loss, Drug
Response Testing (CYP2D6, CYP2C9, CYP2C19); Tamoxifen (2D6 genes); Warfarin
(VKORC1 and CYP2C9
5. Enterolab (USA, www.enterolab.com) Gene Test for Gluten Sensitivity/Celiac Sprue
6. iGenix—Q Trait (USA,
http://www.qtrait.com/)
Asthma, Dyspepsia, Eczema, gluten sensitivity, lactose intolerance, mold allergies,
norwalk virus, stroke (after cardiac surgery), post-operative cognitive dysfunction,
percentage body fat, obesity, learning and memory, hemochromatosis, increased drug
addiction, alcohol and nicotine response, alcohol metabolism, Warfarin (CYP2C9 gene)
7. Psynomics (USA, www.psynomics.com) Bipolar disorder and major depression, selective serotonin reuptake inhibitors
8. Seqwright (USA, www.seqwright.com) Genomic Profiling Service
Group C: companies making clear that their website is not directed to minors, but don’t explicitly say that they would refuse genetic testing in
minors on parental request
1. Biomarker Pharmaceuticals (USA,
www.geneessence.com)
Gene Essence Report
2. CyGene Direct (USA,
www.cygenedirect.com)
Bone Health Genetics (Osteoporosis DNA Analysis), Vision Health Genetics (Glaucoma &
Macular Degeneration DNA Analysis), Blood Clotting Genetics (Thrombosis DNA
Analysis), StrokeScan DNA Analysis, Metabolic Health Assessment (Metabolic Health
Assessment DNA Analysis)
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same breath, some also allow parents to sign a consent form
for their child (as in the case of Consumer Genetics and
Seqwright), order and set up an account for their services on
behalf of his or her child (as in the case of 23andme), or fill in
risk assessment questionnaires, and order genetic tests (as in
the case of DNAdirect). Four companies (23andme, DNA
direct, iGenix-Q Trait, Psynomics) underline in similar
words that the parent or guardian assumes full responsibility
for ensuring that the information that he/she provides about
his or her child is kept secure and that the information
submitted is accurate. None of the eight companies accept
test requests directly from adolescents without the supervi-
sion of a parent. For example iGenix states that their ‘‘ser-
vices are not intended for unsupervised use by children
under the age of 18.’’
Companies which make clear that their website
is not directed towards minors
Four companies of the 29 (14%) (Table 1 group C, and
Table 3) make clear that their website is not directed to
children under 18 years of age. Cygene Direct describes
that ‘‘…this website is not intended for, or designed to
attract, individuals under the age of 18.’’ However, it
remains unclear whether these companies would refuse to
perform genetic tests upon parental request.
Companies suggesting that in order to be tested,
applicants should be 18 years of age or older
Four companies (14%; 4/29) compose group D (Table 1
group D, and Table 4); information on their websites sug-
gests that test applicants should have reached the age of
legal majority in order to be tested. For example, Suracell
states that ‘‘when an individual requests participation in the
Suracell Program, they must certify that they are 18 years of
age or older’’; Inneova asks applicants to confirm that ‘‘I am
an adult over the age of 18 years (or over the age of consent
in jurisdiction where such age is higher than 18 years)’’.
Navigenics also states that ‘‘Given the ethical, privacy and
informed consent considerations regarding genetic testing
of minors for predisposition or carrier status of adult-onset
genetic disorders, Navigenics does not knowlingly collect
or use information from minors under the age of 18.’’
Discussion
Our findings suggest that certain companies appear to have
an awareness of some of the social, ethical and legal issues
pertaining to genetic testing in minors. However, our
results also demonstrate that other companies challenge
the ethical framework of protecting children as they are
willing to provide genetic testing in a pediatric population.
Because of the sensitive nature of genetic information, the
right to autonomous decision making and self-determina-
tion, confidentiality and privacy issues, we feel it is
important to take specific notice of direct-to-consumer
genetic testing issues for minors.
Clinical guidelines focusing on genetic testing in minors
have emphasized that the best interest of the child is par-
amount and that perceived benefits and risks of testing
must be carefully weighed when considering a genetic test
in minors. In the context of a genetic test for a late onset
disorder (e.g. BRCA), testing has only been recommended
when ‘‘established, effective, and important medical
Table 1 continued
Company DNA tests offered
3. Salugen—DNA services of America
(USA, www.salugen.com;
www.genotrim.com)
Genotrim (obesity), Haveos (addiction), Spagen (nutrigenomic)
4. MediChecks (UK, www.medichecks.com Various genetic tests for monogenetic and complex disorders, as well as other blood tests
Group D: companies suggesting that in order to be tested, applicants should be 18 years of age or older
1. Navigenics (USA, www.navigenics.com) ‘Navigenics Health Compass’
2. Genelex (USA, www.healthanddna.com) Nutritional Genetic Profile with a nutritionist consultation, Celiac Disease DNA Test,
Hemochromatosis DNA Test, Periodontal Disease DNA Test, Narcolepsy DNA Test);
CYP2D6 (cytochrome P450 2D6); CYP2C9 (cytochrome P450 2C9); CYP2C19
(cytochrome P450 2C19); CYP1A2 (cytochrome P450 1A2); NAT2 (N-acetyltransferase
2); DPD (dihydropyrimidine dehydrogenase); UGT1A1 (UDP-glucuronosyltransferase);
5HTT (Serotonin Transporter)
3. Inneova (Canada, www.inneova.com) Anti-aging test, Hormone replacement therapy management, Weight control, optimal
health test, vascular risk test, cancer risk test, dermatogenetic test, Pharmacogenomics
test, Whole DNA Sequencing (through Knome)
4. Suracell (USA, www.suracell.com) Personal DNA analysis
P. Borry et al.
123
treatment’’ [14] can be offered or when testing ‘‘provides
scope for treatment which to any essential degree prevents,
defers or alleviates the outbreak of disease or the conse-
quences of the outbreak of disease’’ [15]. The rationale
behind this option is that predictive and presymptomatic
testing for adult-onset disease ‘‘should be delayed until the
person is old enough to make an informed choice’’ [16].
The same notion applies to carrier testing, where it has
been advanced that ‘‘For carrier status for conditions that
will be important only in reproductive decision making,
testing of children should be discouraged until the child is
able to participate fully in the decision to be tested’’ [17].
In the case of presymptomatic and predictive genetic
testing for conditions which manifest in childhood, the
current policy depends on whether this condition can be
effectively treated or prevented. If preventive or thera-
peutic measures are available, ‘‘there are good reasons to
comply or to actively bring up the possibility of a test.
Table 2 Group B. List of companies allowing genetic testing in minors upon parental request and/or authorization
Company Policy
1. 23andme ‘‘You represent that you are eighteen (18) years of age or older. You are guaranteeing that the sample you provide is
your saliva; if you are completing this consent form on behalf of a person for whom you have legal authorization,
you are confirming that the sample provided will be the sample of that person.’’ (Consent and legal agreement,
https://www.23andme.com/about/consent, accessed 10 January 2009)
‘‘23andme is committed to protecting the privacy of children, as well as adults. Neither 23andme nor any of its
services are designed or intended to attract children under the age or 13. A parent or guardian, however, may
order and set up an account for our services on behalf of his or her child. The parent or guardian assumes full
responsibility for ensuring that the information that he/she provides to 23andme about his or her child is kept
secure and that the information submitted is accurate.’’ (Privacy statement,
https://www.23andme.com/about/privacy, accessed 10 January 2009)
2. Consumer genetics ‘‘Signature (Parent or Guardian if patient is a minor’’ for Asthma Drug Response Test. (no information for other
tests)
Informed consent form, http://www.consumergenetics.com/pdfs/Asthma-Brochure.pdf, accessed 10 January 2009
3. Decode ‘‘Either you are the owner of the sample or have full authority of the owner or subject of the sample to submit the
sample for processing.’’ (The deCODEme concept, http://www.decodeme.com/index/about_concept, accessed 10
January 2009)
4. DNA direct ‘‘We are committed to protecting the privacy of children. Neither DNA Direct nor any of its services are designed or
intended to attract children under the age of 13. We do not collect Personally Identifiable Information from any
person we actually know is under the age of 13. A parent or guardian, however, may do any of the following
things on behalf of his or her child: (a) complete a risk assessment questionnaire; (b) register to save partially-
completed risk assessment questionnaires; (c) save partially-completed risk assessment questionnaires; (d) order
genetic tests; and (e) register to receive promotional communications. The parent or guardian assumes full
responsibility for ensuring that the information that it provides to DNA Direct about his or her child is kept secure
and that the information submitted is accurate.’’
Privacy Policy, http://www.dnadirect.com/patients/about/privacy.jsp, accessed 10 January 2009
5. Enterolab ‘‘Tests for persons under the age of 18 must be ordered by a parent or legal guardian.’’
Instructions for completion of a successful order, https://www.enterolab.com/CustomerPages/Createorder1.aspx,
accessed 10 January 2009
6. iGenix—Q Trait ‘‘The iGenix services are not intended for unsupervised use by children under the age of 18. A parent or legal
guardian, however, may order and set up an account for our services on behalf of his or her child. The parent or
guardian assumes full responsibility for ensuring that the information that he/she provides to iGenix about his or
her child is kept secure and that the information submitted is accurate.’’
Privacy Policy, http://www.qtrait.com/privacy_policy, accessed 10 January 2009
7. Psynomics ‘‘We are committed to protecting the privacy of children. Neither Psynomics nor any of its services are designed or
intended to attract children under the age of 18. We do not collect Personally Identifiable Information from any
person we actually know is under the age of 14. A parent or guardian, however, may do any of the following
things on behalf of his or her child, if over the age of 13 and under the age of 18: (a) order genetic tests; and (b)
register to receive communications. The parent or guardian assumes full responsibility for ensuring that the
information that it provides to Psynomics about his or her child is kept secure and that the information submitted
is accurate.’’
Privacy Policy, https://www.psynomics.com/pdf/privacy_policy.pdf, accessed 10 January 2009
8. Seqwright ‘‘I am at least 18 years of age OR I am the legal guardian of the client (if the client is younger than 18 years old or
unable to sign below)’’
Personal information and acknowledgment form, https://gps.seqwright.com/orderform.php, accessed 10 January
2009
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However, if the preventive and therapeutic measures will
be deferred to a later time, the justification for immediate
testing is less compelling and careful, supportive counsel-
ling will often be appropriate whether or not testing hap-
pens at that time’’[18]. When no treatment or prevention is
available, ‘‘there are both benefits and risks, and usually
neither the benefits nor the risks completely outweigh each
other. Genetic testing could be considered if this would be
to the psychological or social benefit of the child and his
family’’ [18].
Since the companies studied offer a wide variety of
tests, many of which have yet to be offered through the
traditional health care system, it could be said that these
companies offer services that are not necessarily included
in the scope of the existing clinical guidelines regarding
minors. However, if we only consider tests already
accepted in a clinical setting, can we expect these com-
panies to follow established guidelines? According to DNA
Direct’s website ‘‘a parent or guardian (…) may do any of
the following things on behalf of his or her child: (…) (d)
order genetic tests’’ (Table 2). The company adds that in
this case ‘‘The parent or guardian assumes full responsi-
bility for ensuring that the information that it provides to
DNA Direct about his or her child is kept secure and that
Table 3 Group C. List of companies which make clear that their website is not directed to minors, but donot explicitly say that they would
refuse genetic testing in minors on parental request
Company Policy
1. Biomarker Pharmaceuticals ‘‘This site is not directed to children under 18. We do not knowlingly collect personally identifiable
information from children under 18. If a parent or guardian becomes aware that his or child has
provided us with any personal information without their consent, he or she would notify us
immediately. If we become aware that a child under 18 has provided us with personal information
we will delete such information from our files.’’
Privacy policy, http://www.geneessence.com/our-labs/privacy-policy.html, accessed 10 January 2009
2. CyGene Direct ‘‘You should also be aware that this website is not intended for, or designed to attract, individuals
under the age of 18. We do not collect personally identifiable information from any individual we
actually know is an individual under the age of 18. We also ask that they not use this website or
provide us with any information.’’
Privacy Policy, http://www.dnatestnow.com/t-privacy.aspx, accessed 10 January 2009
3. Salugen—DNA services of America The Salugen website is intended for use by adults only. Minors under the age of 18 years may not use
this website.
Terms & Conditions http://www.salugen.com/terms-conditions.html, accessed 10 January 2009
5. MediChecks ‘‘Children should always get permission from their parents before sending any information about
themselves (such as their names, e-mail addresses, and phone numbers) over the internet, to us or to
anyone else. We won’t knowlingly allow anyone under 18 to register with our site.’’
Privacy Policy, http://www.medichecks.com/privacy.cfm, accessed 10 January 2009
Table 4 Group D. List of companies suggesting that in order to be tested, applicants should be 18 years of age or older
Company Policy
1. Navigenics ‘‘This website is not directed toward minors under 18 years of age. Given the ethical, privacy and informed consent
considerations regarding genetic testing of minors for predisposition or carrier status of adult-onset genetic disorders,
Navigenics does not knowlingly collect or use information from minors under the age of 18.’’
Privacy Policy, http://www.navigenics.com/policies/Privacy/, accessed 10 January 2009
2. Genelex ‘‘This test is only available to people 18 or older.’’ for Nutritional Genetic Profile. (No information for other tests)
Order Nutritional genetic testing, http://www.healthanddna.com/professional/nutrigenetics.html, accessed 10 January
2009
3. Inneova ‘‘I confirm that I am an adult over the age of 18 years (or over the age of consent in jurisdictions where such age is
higher than 18 years), that I enter into this Agreement voluntarily, and that I am legally entitled to do so.’’
Terms & Conditions and Statement of Consent, http://www.inneova.com/contenu.php?page=terms.php, accessed 10
January 2009
4. Suracell When an individual requests participation in the Suracell Program, they must first certify that they are 18 years of age
or older, and that they consent to supply Suracell with personal health information, such as their specimens and
answers to the Suracell Environmental and Lifestyle Questionnaire.
Privacy Policy, http://www.suracell.com/privacy.aspx, accessed 10 January 2009
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the information submitted is accurate’’ (Table 2). If they
are indeed strictly following this policy, it would conflict
with existing professional guidelines as they are providing,
among other tests, genetic tests for breast cancer (BRCA1,
BRCA2). This being said, due to the limitations of a web
based analysis, it is impossible to ascertain exactly how
this company would react if a parent were to order BRCA
testing for their child in reality. After all, this company
does require that consumers contact a company counselor
before ordering BRCA testing, and therefore, it is possible
that a parental request for a child to be tested could be
denied at this stage regardless of what is written on their
website. Moreover, DNA Direct underlines that they are
operating ‘‘according to the standards and guidelines of the
National Society of Genetic Counselors and the American
College of Medical Genetics, using board-certified per-
sonnel under the supervision and authorization of a phy-
sician’’ [19]. Both professional bodies hold a clear position
on testing in minors. The American College of Medical
Genetics states that ‘‘If the medical or psychosocial bene-
fits of a genetic test will not accrue until adulthood, as in
the case of carrier status or adult-onset diseases, genetic
testing generally should be deferred. Exceptions to this
principle might occur when the adolescent meets condi-
tions of competence, voluntariness, and adequate under-
standing of information’’ [20]. The National Society of
Genetic Counselors states that when possible, as in the case
of late-onset disorders, ‘‘the child should be involved in the
decision about whether or not to be tested’’ [21]. This type
of ambiguity concerning which policy is being followed
should be reduced to a minimum and private companies
offering genetic tests directly to consumers should be
explicit about which standards they are adhering to, par-
ticularly with respect to testing in minors.
As alluded to previously, in view of the major ethical
considerations that surround predictive genetic testing and
carrier testing in minors, one could question whether the
same guidelines apply for tests that are described by
companies as not being for the purpose of preventing,
diagnosing or treating medical conditions. It is interesting
to note that many companies offering DTC genetic testing
declare that their services are not clinical services and
should not be used as a basis for making medical decisions.
For example, Consumer Genetics writes in its Authoriza-
tion and Disclosure form that ‘‘all materials and products
provided by Consumer Genetics, Inc. are provided for
informational purposes only and are not by themselves
intended for diagnosis or treatment of any disease or dis-
order’’ [22]. The privacy policy found on iGenix, Inc’s
website describes that its ‘‘service is not a test or kit
designed to diagnose disease or medical conditions.
Information you receive from the iGenix, Inc. service is not
intended to be medical advice’’ [23]. Likewise, 23andme
emphasizes in its Terms of Service that their ‘‘service
content is not to be used, and is not intended to be used, by
you or any other person to diagnose, cure, treat, mitigate or
prevent a disease or other impairment or condition, or to
ascertain your health’’ [24].
Various companies state that the predictive value of
their genetic tests is insufficient as a useful basis for per-
sonalized nutritional and lifestyle recommendations. It
remains, however, a possibility that consumers will over-
estimate the predictive value of the genetic tests [25].
Knowledge of an increased disease risk may affect the
relationship between parents and children, and engender in
the parents a sense of responsibility both for the disorder
itself and for protecting the infant from its impact [26].
Excessive attention to genetic risk information could also
decrease the attention to non-genetic factors in disease
development and lead to an overestimation of (non-vali-
dated) risk information [27].
Moreover, by accepting children’s samples submitted by
their parents, some companies are neglecting some of their
own positions with regard to the sensitive and private
character of genetic information. SeqWright states that
‘‘your genetic information is extremely sensitive. In fact, it
may be the most sensitive information there is and as new
discoveries are made, and more is learned about what your
genes say about you, this information is likely to become
evermore sensitive over time’’ [28]. deCODE claimed that
‘‘the only people who should be able to see your genetic
information are you and those with whom you choose to
share it’’ [29]. Contrary to the latter two companies, which
do provide testing in children, it was precisely because of
these ‘‘ethical, privacy and informed consent consider-
ations regarding genetic testing of minors for predisposi-
tion or carrier status of adult-onset genetic disorders’’ [30]
that Navigenics decided not to process samples or infor-
mation from children who have not reached the age of
majority.
The Human Genetics Commission (HGC) also raised
the issue that any genetic testing service ‘‘that requires a
sample to be collected at home or to be tested by the
consumer at home runs the risk of samples being submitted
for testing without proper consent’’ [31]. Therefore, it
recommended that companies elaborate mechanisms to
prevent non-consensual testing. During focus groups
undertaken in preparation of the HGC report, particular
concern was raised about how a company would be able to
verify that a subject had consented to the test [32]. The
HGC also supports the recommendations of the Advisory
Committee on Genetic Testing’s Code of Practice (1997)
[33] which promotes the practice of not supplying genetic
testing services direct-to-the-public to those under the age
of 16 or to those not able to make a competent decision
regarding testing.
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The sale of clinically unvalidated genetic tests, as is
done by many companies whom acknowledge this, to
adults is controversial. It becomes more controversial when
these tests are being sold to adolescents or minors who are
not able to decide for themselves. Companies that are
selling clinically validated tests should adhere to all pro-
fessional standards and guidelines and should be offering
the same quality of services as someone would expected in
a centre for clinical genetics.
Finally, it is interesting, yet perhaps not completely
unexpected, that while some companies’ websites do not
explicitly elaborate a policy about whether or not they test
children upon parental request, they do take the time to
explain to whom their website is directed or not directed.
Cygene’s website, for example, clearly states that ‘‘You
should also be aware that this website is not intended for,
or designed to attract, individuals under the age of 18.’’
DNA Direct underlines that their services are not
‘‘designed or intended to attract children under the age of
13.’’ The age of 13 can be explained by the fact that in the
USA specific regulations (i.e. the Children’s Online Pri-
vacy Protection Act) and guidelines (i.e. CARU guidelines
for interactive media) apply to advertisements that are
directed to children under the age of 13.
Finally, it is clear that our web-based method of analysis
poses limitations to knowing what companies are really
doing when faced with a request to test a child. This is true
for all companies, regardless of the categories in which
they have been classified. Furthermore, simply because a
company’s website does not include any information
regarding testing in minors, this does not necessarily
exclude the possibility that they do have a sound policy. In
this regard, further research is necessary in which compa-
nies are directly approached in order to collect data
regarding the number of tests they actually perform on
children, and to compare if the position found on their
webiste fully reflects what is done in practice. Moreover,
the fact that this article only focuses on DTC genetic
testing in children does not imply that there are no concerns
regarding testing in adults. As was briefly mentioned in the
introduction, this type of DTC service has raised a number
of questions and concerns regarding many aspects of test-
ing, including the clinical validity and utility of the tests.
Conclusion
We have analyzed the websites of 29 companies which sell
health-related genetic tests directly to consumers. Many of
these companies have not integrated a clear policy on their
website regarding whether or not they would process
samples coming from minors. It would be responsible for,
at least, the companies selling genetic tests also offered in a
clinical setting, to consider how to incorporate standards
established by professional guidelines. This being said,
even for genetic tests that are described as ‘not being ser-
vices which should be used to make medical decisions’,
the same best interest considerations, respect for autonomy,
confidentiality and privacy suggest that children should
not be tested unless there are immediate benefit for the
child.
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